Patents by Inventor Zahra Jawad

Zahra Jawad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141039
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Application
    Filed: June 13, 2023
    Publication date: May 2, 2024
    Inventors: Dhan Sidhartha CHAND, Zahra JAWAD, Olga IGNATOVICH, Nicola Anne RAMSAY, Spencer CAMPBELL, Beth WENSLEY, Emmanuel Cyrille Pascal BRIEND, K. Mark BUSHELL, Benjamin Maxime MORIN, Veronica Franciszka ILKOW
  • Patent number: 11718669
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: August 8, 2023
    Assignee: AGENUS INC.
    Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
  • Publication number: 20230014036
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Application
    Filed: August 10, 2022
    Publication date: January 19, 2023
    Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
  • Publication number: 20210130495
    Abstract: Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (Fc?RIIIA) relative to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particular useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for making these heterodimeric proteins.
    Type: Application
    Filed: September 28, 2020
    Publication date: May 6, 2021
    Inventors: Dhan Sidhartha Chand, Zahra Jawad, Veronica Franciszka Ilkow